Madrigal Pharmaceuticals, Inc.
MDGL$5.10B
Mid CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWEST CONSHOHOCKEN528 employees
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Mar 15, 2026
TomorrowMarket Overview
Stock performance and key metrics
MDGL News
Catalyst Timeline
2 upcoming, 1 past
Phase 3Next
Resmetirom Phase 3 Results Expected
March 2026~EstimatedResmetirom1,000
Primary completion for Resmetirom trial (NCT04951219) in Non-Alcoholic Fatty Liver Disease
Source1 more catalyst beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Resmetirom | Phase 3 | NASH | - | - |
MGL-3196 | Phase 3 | Heterozygous Familial Hypercholesterolemia | - | - |
Heterozygous Familial Hypercholesterolemia
1 drug in this indication
NASH
1 drug in this indication
Non-Alcoholic Fatty Liver Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply